31 related articles for article (PubMed ID: 38592722)
1. Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
Tan TJ; Sammons S; Im YH; She L; Mundy K; Bigelow R; Traina TA; Anders C; Yeong J; Renzulli E; Kim SB; Dent R
Clin Cancer Res; 2024 Apr; 30(7):1240-1247. PubMed ID: 38236575
[TBL] [Abstract][Full Text] [Related]
2. Combination of Osimertinib and Olaparib Therapy to Treat Non-Small Cell Lung Cancer and High-Grade Serous Ovarian Carcinoma: A Case Report.
Lin J; Welch S; Sanatani M; Ramadan S
Curr Oncol; 2024 Jan; 31(1):558-565. PubMed ID: 38275832
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
Marchetti C; Ataseven B; Perrone AM; Cassani C; Fruscio R; Sassu CM; Apostol AI; Harter P; De Iaco P; Camnasio CA; Moubarak M; Giannarelli D; Scambia G; Fagotti A
Gynecol Oncol; 2024 May; 187():170-177. PubMed ID: 38788514
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Pitiyarachchi O; Ansell PJ; Coleman RL; Dinh MH; Holman L; Leath CA; Werner T; DiSilvestro P; Morgan M; Tew W; Lee C; Cunningham M; Newton M; Edraki B; Lim P; Barlin J; Spirtos NM; Tewari KS; Edelson M; Reid T; Carlson J; Friedlander M
Gynecol Oncol; 2024 May; 187():221-226. PubMed ID: 38821039
[TBL] [Abstract][Full Text] [Related]
5. The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study.
Mhawech-Fauceglia P; McCarthy D; Tonooka A; Scambia G; Garcia Y; Dundr P; Mills AM; Moore K; Sanada S; Bradford L; Stella GC; Bookman M; Sharma SK; Selle F; Molinero L; He Y; Khor V; Landen C; Lin YG
Gynecol Oncol; 2024 Mar; 186():17-25. PubMed ID: 38554625
[TBL] [Abstract][Full Text] [Related]
6. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial.
Glade Bender JL; Pinkney K; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Fox E; Weigel BJ; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
Oncologist; 2024 May; ():. PubMed ID: 38815151
[TBL] [Abstract][Full Text] [Related]
7.
Mayor P; Gay LM; Lele S; Elvin JA
Gynecol Oncol Rep; 2017 Aug; 21():57-60. PubMed ID: 28706968
[TBL] [Abstract][Full Text] [Related]
8. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
[TBL] [Abstract][Full Text] [Related]
9. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
10. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
[TBL] [Abstract][Full Text] [Related]
11. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Harter P; Mouret-Reynier MA; Pignata S; Cropet C; González-Martín A; Bogner G; Fujiwara K; Vergote I; Colombo N; Nøttrup TJ; Floquet A; El-Balat A; Scambia G; Guerra Alia EM; Fabbro M; Schmalfeldt B; Hardy-Bessard AC; Runnebaum I; Pujade-Lauraine E; Ray-Coquard I
Gynecol Oncol; 2022 Feb; 164(2):254-264. PubMed ID: 34952708
[TBL] [Abstract][Full Text] [Related]
14. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Labidi-Galy SI; Rodrigues M; Sandoval JL; Kurtz JE; Heitz F; Mosconi AM; Romero I; Denison U; Nagao S; Vergote I; Parma G; Nøttrup TJ; Rouleau E; Garnier G; El-Balat A; Zamagni C; Martín-Lorente C; Pujade-Lauraine E; Fiévet A; Ray-Coquard IL
Ann Oncol; 2023 Feb; 34(2):152-162. PubMed ID: 36564284
[TBL] [Abstract][Full Text] [Related]
15. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]